March 25th 2025
Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.
February 17th 2025
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
Catalent, Ethicann Partner on Fast-Dissolve Cannabinoid Treatment for MS Spasticity
December 5th 2019Catalent and Ethicann Pharmaceuticals have announced a partnership aimed at developing a new combination pharmaceutical-grade CBD and THC product to treat MS spasticity using Catalent’s orally disintegrating tablet technology.
Improving the Patient Experience with High Viscosity/High Volume Drugs
October 17th 2019On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience at CPhI Worldwide.
Perspectives on Quality Attributes of Drug Products Containing Nanomaterials
In this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.